Creative Biolabs is a leading service provider of high-quality antibody and peptide discovery against MERS-CoV. Anti-Bacteria Biomolecular Discovery is one of our most distinctive platforms. Based on this advanced and innovative technology platform, we can help our global clients explore the potential and well-recognized targets for anti-MERS-CoV antibody or peptide.
Fig. 1 3D image of middle East respiratory
syndrome coronavirus.
Middle east respiratory syndrome-related coronavirus (MERS-CoV) is a new member of beta group of coronavirus, Betacoronavirus, lineage C. It is a positive-sense, single-stranded RNA virus which causes a viral respiratory illness, middle east respiratory syndrome (MERS). Symptoms of the disease include cough, fever, and shortness of breath, and can lead to pneumonia and kidney failure. This MERS-CoV has so far been shown to infect humans, camels, and bats. It is believed to have started in bats and then transmitted to camels. From camels, it can pass to humans, but how this happens is still unclear.
MERS-CoV- spike (S) protein is a 1353-amino-acid type I membrane glycoprotein that is responsible for receptor binding, membrane fusion, and the viral entry during MERS-CoV infection. The two components of S protein are S1 containing the receptor binding domain (RBD) and S2 containing the fusion peptide. The RBD of S1 subunit is involved in the binding to the cellular receptor dipeptidyl peptidase 4 (DPP4). The S2 subunit is responsible for driving viral and target cell membrane fusion. In a word, MERS-CoV protein is essential for viral attachment to host cells and virus-cell membrane fusion. As thus, S protein serves as a very promising target target for anti-MERS-CoV agents.
Neutralizing antibodies are induced by antigens to protect cells from pathogen infection. Most neutralizing antibodies function at the earliest steps of viral infection through blocking interaction of the virus with cellular receptors and prevent entry into host cells. It has been reported that RBD of S protein efficiently elicits neutralizing antibodies against MERS-CoV by blocking viral entry at the binding step. Currently, most human mAbs against MERS-CoV have been developed, such as LCA60, MERS-4, REGN3048, 1E9, etc. The anti-MERS-CoV mechanism of these antibodies is to specifically recognize neutralizing epitopes in S protein and then neutralize infection. In addition, anti-MERS-CoV peptides are alternative drugs that are potential to treat MERS-CoV infection. It has been reported peptides derived from the S2 subunit HR2 domain exert a good anti-MERS-CoV activity.
Fig.2 Structural basis of MERS-CoV infection inhibited by RBD-specific neutralizing antibodies (Du et al. 2017).
With the years of experience in the field of discovery of antibody/peptide targeting virus, Creative Biolabs is confident in offering the first-in-class service of MERS-CoV antibody/peptide discovery for all global customers. Our powerful AntInfect™ Platform is optimal for anti-virus biomolecular discovery. Besides, we are a well-recognized leader in the field of single domain antibody and able to provide a series of single domain antibody discovery services with the best quality and low cost. Please don't hesitate to contact us for more information and a detailed quote.
Reference:
